Related Experiment Video

Updated: Jun 21, 2026

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

An update on treatment and prevention strategies for Alzheimer's disease

Judith Neugroschl1, Mary Sano

  • 1James J. Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA.

Current Neurology and Neuroscience Reports
|August 12, 2009
PubMed

Insights

Alzheimer's disease treatments are evolving, with new strategies targeting amyloid and tau pathology. Research also explores novel approaches like RAGE inhibitors and anti-inflammatory agents to combat this growing neurodegenerative disease.

Area of Science:

  • Neuroscience
  • Gerontology
  • Pharmacology

Background:

  • Aging population increases Alzheimer's disease (AD) incidence and prevalence.
  • Current AD treatments manage symptoms but do not halt disease progression or offer a cure.
  • Significant unmet need exists for disease-modifying therapies for Alzheimer's.

Purpose of the Study:

  • To review recent data on therapeutic strategies for Alzheimer's disease.
  • To discuss novel treatments targeting amyloid and tau pathologies.
  • To provide an update on pharmacologic and nonpharmacologic prevention trials.

Main Methods:

  • Literature review of recent data on AD treatment strategies.
  • Discussion of novel therapeutic targets including RAGE inhibitors and mitochondrial modification.
  • Analysis of results from prevention trials.

Main Results:

  • Emerging treatments focus on amyloid and tau pathology.
  • Novel strategies include RAGE inhibitors, Dimebon for mitochondrial modification, anti-inflammatory agents, and cholesterol-lowering drugs.
  • Prevention trials offer insights into pharmacologic and nonpharmacologic interventions.

Conclusions:

  • New therapeutic avenues are being explored to halt Alzheimer's progression.
  • Targeting underlying pathologies and prevention are key research areas.
  • Future treatments may offer more effective disease modification and prevention.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...